About us

Management Team

  • Mr. Paul Cassingham, attorney at law, international-licensing consultant

    Mr. Paul Cassingham is a senior legal consultant at Eiger, a renowned independent law firm in Taiwan, with offices in Taipei and Shanghai. Before joining Eiger, Mr. Cassingham was a partner at several law firms in the U.S., Hong Kong, and Taiwan. Over the past 30 years, he represented many multinationals in the U.S., Europe, and other countries, in charge of legal affairs in Asia-Pacific, with customers spanning a wide range of fields, including medicine, consumer products, biotech, energy, electronics, chemicals, engineering, manufacturing, finance, real estate, and movie production.


    Mr. Cassingham has been an active member of AmCham Taipei over the past 25 years, serving as its chairman during 1999-2000 and as chair of the Government Relations Committee now, in charge of AmCham Taipei's stance and policy direction on Taipei-U.S. economic/trade issues, including Taiwan's accession to WTO and Government Procurement Agreement (GPA), Taiwan-U.S. Trade and Investment Framework Agreement (TIFA), and Trans-Pacific Partnership (TPP).


    Mr. Cassingham has publicized/delivered 50 papers/speeches and frequently accepted interviews by TV and radio-broadcast stations, commenting on foreign investments and Taiwan-U.S. political and economic/trade relationship, in addition to hosting "Business Review" talk show at Unique Satellite TV. He graduated from law school of Northwestern University and University of Michigan of the U.S.

  • Dr. Zhuan Gzhe-Ren Drug Development Consultant

    With over 20 years of experience in bio-pharmaceutical development, Dr. Zhuan Gzhe-Ren specializes in the market development, manufacturing, technical process development, and bio-pharmaceutical plant design.
    After obtaining a doctorate degree in Chemical Engineering from the Massachusetts Institute of Technology, Dr. Zhuan worked for Merck & Co., Inc., San Fu Chemical Co., (joint venture with US Air Products & Chemicals Inc.), Hoffmann-La Roche Ltd. US and Bristol-Myers Squibb Company. Then he served as general manager and chief executive at the R&D center, China Chemical & Pharmaceutical Co., Ltd.

    Dr. Zhuan has abundant experience in bio-pharmaceutical industry, with such stints as independent director and consultant of technical process/strategy, bio-pharmaceutical plant design, and cGMP regulations. He was biotech consultant of Uni-President Enterprises Corp., chemical and medical consultant of Industrial Technology Research Institute, committee member of the MEMS program of National Chung-Shan Institute of Science & Technology, committee member of ICH Taiwan, committee member of the Center for Drug Evaluation Taiwan, committee member of the technical project, Ministry of Economic Affairs, and consultant of the bio-pharmaceutical development team, Ministry of Economic Affairs.

  • Dr. Shao-Hsuan Kao Drug Development Consultant

    Dr. Shao-Hsuan Kao Drug obtained his Ph. D. in Science from Institute of Biochemistry and Molecular Biology, National Taiwan University. He has conducted postdoctoral research at Centers of Genomic Medicine, National Taiwan University Hospital and Institute of Biomedical Sciences, Academia Sinica. He joined a team to participate in the 4th WeWin Entrepreneurship Competition hold by Taiwan Industrial Bank (the former O-Bank) and the team came in second in the race. He also conducted the product development and functional activity tests for biotechnology companies, and serves as a consultant for Pingtung Agricultural Biotechnology Park.

    Dr. Shao-Hsuan Kao is currently working at Chung Shan Medical University. He has been the director of the Industry Cooperation and Incubation Center of the Research and Development Office, the director of the Student Assistance Division of the affiliated hospital. The research interests are mainly focused on analyzing the effects of environmental bioaerosols on human immunoreactivity, exploring the molecular pathogenesis of allergens, and understanding the biological activities and mechanisms of natural molecules in anti-inflammatory and anti-tumor. Today, a total of more than 60 SCI papers have been published by Dr. Kao and his research team.